220801-66-1

Basic information

• Product Name: METHYL 2-(5-BROMO-2-HYDROXYPHENYL) ACETATE
• Synonyms: METHYL 2-(5-BROMO-2-HYDROXYPHENYL) ACETATE;METHYL 2-(5-BROMO-2-HYDROXYPHENYL);Benzeneacetic acid,5-broMo-2-hydroxy-, Methyl ester;5-Bromo-2-hydroxybenzeneacetic acid methyl ester
• CAS NO: 220801-66-1
• Molecular Formula: C₉H₉BrO₃
• Molecular Weight: 245.07
• Mol File: 220801-66-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 317.143 °C at 760 mmHg
• Flash Point: 145.603 °C
• Appearance: /
• Density: 1.562±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.84±0.43(Predicted)
• CAS DataBase Reference: METHYL 2-(5-BROMO-2-HYDROXYPHENYL) ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-(5-BROMO-2-HYDROXYPHENYL) ACETATE(220801-66-1)
• EPA Substance Registry System: METHYL 2-(5-BROMO-2-HYDROXYPHENYL) ACETATE(220801-66-1)

Safety Data

• Hazardous Substances Data: 220801-66-1(Hazardous Substances Data)

Usage

General Description

Methyl 2-(5-bromo-2-hydroxyphenyl) acetate is a chemical compound with the molecular formula C9H9BrO3. It is a derivative of acetic acid and contains a bromine atom and a hydroxyphenyl group. METHYL 2-(5-BROMO-2-HYDROXYPHENYL) ACETATE is commonly used in the synthesis of pharmaceuticals, agrochemicals, and organic materials. It has potential applications in the development of drugs for various medical conditions. Its chemical structure and properties make it a valuable intermediate for the production of diverse functionalized molecules. However, as with all chemicals, proper handling and safety precautions should be followed when working with methyl 2-(5-bromo-2-hydroxyphenyl) acetate.

InChI:InChI=1/C9H9BrO3/c1-13-9(12)5-6-4-7(10)2-3-8(6)11/h2-4,11H,5H2,1H3

Upstream product

• 67-56-1 methanol 
• 614-75-5 2-Hydroxyphenylacetic acid 
• 38692-72-7 2-hydroxy-5-bromo-phenylacetic acid 

Downstream Products

• 205318-13-4 (R)-methyl <5-bromo-2-(1-phenylethoxy)phenyl>acetate 
• 220801-67-2 (S)-methyl <5-bromo-2-(1-phenylethoxy)phenyl>acetate 
• 1338928-87-2 2-(5-bromo-2-(4-iodophenoxy)phenyl)acetic acid 
• 1338928-46-3 2-(5-bromo-2-(4-bromophenoxy)phenyl)acetic acid 
• 1338928-86-1 ethyl 2-(5-bromo-2-(4-iodophenoxy)phenyl)acetate 
• 1338928-45-2 methyl 2-(5-bromo-2-(4-bromophenoxy)phenyl)acetate 
• 1333225-29-8 methyl 2-(5-bromo-2-(tert-butyldimethylsilyloxy)phenyl)-3-(4-fluorophenyl)-3-oxopropanoate 
• 1426960-33-9 2-(4-fluorophenyl)-5-(11-fluoro-6H-pyrido[2',3':5,6][1,3]oxazino[3,4-a]indol-2-yl)-N-methyl-6-(N-methylmethanesulfonamido)-1-benzofuran-3-carboxamide 
• 1621705-60-9 (2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl)boronic acid 
• 1616372-73-6 methyl 2-(5-bromo-2-(2-(dimethylamino)ethoxy)phenyl)acetate 
• 1243783-40-5 methyl 2-(5-bromo-2-ethoxyphenyl)acetate 
• 1454928-36-9 methyl 2-(2-ethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate 
• 1333244-21-5 5-(3-(4-cyanobenzo[d]oxazol-2-yl)-4-methoxyphenyl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylsulfonamido)benzofuran-3-carboxamide 

Relevant articles and documents

Metal-Free Tandem Rearrangement/Lactonization: Access to 3,3-Disubstituted Benzofuran-2-(3H)-ones

A novel metal-free synthesis of 3,3-disubstituted benzofuran-2-(3H)-ones through reacting α-aryl-α-diazoacetates with triarylboranes is presented. Initially, triarylboranes were successfully investigated in α-arylations of α-diazoacetates, however in the presence of a heteroatom in the ortho position, the boron enolate intermediate undergoes an intramolecular rearrangement to form a quaternary center. The intermediate cyclizes to afford valuable 3,3-disubstituted benzofuranones in good yields.

5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS

The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (la) and (lb) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocyticδ leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (la) or (lb), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPARα and PPARδ. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a herapeutically effective amount of a dual antagonist of PPARα and PPARδ.